LBNL Logo ONHS Funding Opportunity Report

RFI Alzheimer’s Research Program (AZRP) Public

Solicitation ID: HT9427RFI2027AZRP

Agency: Department of War/CDMRP

Type: Sources Sought
Deadline: 2026-12-04T16:00:00 ET
Eligibility: Yes (Unrestricted)
Funding: N/A
Doc Type: RFI
Clearance: No
Program Manager: Jared D. Acre
Last Updated: 2026-10-27 16:03
Analyzed File: 2027 AZRP RFI Questions_for posting.docx

Eligibility Reasoning

The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public.

Note: This is an AI-generated summary...

Summary

The Congressionally Directed Medical Research Programs (CDMRP) has issued a Request for Information (RFI) in the form of a stakeholder survey to inform the strategic planning for the Fiscal Year 2027 (FY27) Alzheimer’s Research Program (AZRP). The RFI seeks to identify research gaps and funding priorities from a broad audience, including researchers, clinicians, patients, and federal partners. The survey is structured around three core strategic goals: 1) Understanding risk factors to reduce and prevent Alzheimer's Disease and related dementias (AD/ADRD), with a focus on military-relevant exposures and veteran cohorts; 2) Improving early and accurate diagnosis and prognosis through the development of biomarkers (digital, blood-based, neuroimaging) and methods to distinguish AD/ADRD from chronic traumatic brain injury (TBI); and 3) Improving the quality of life for individuals with AD/ADRD and their caregivers through non-pharmacological and behavioral interventions. This RFI is for planning purposes only and is not a solicitation for proposals.

Overall Technical Areas

AD/ADRD Risk Factor IdentificationPrecision Prevention StrategiesDifferential Risk Pathway AnalysisMilitary Exposure Risk AnalysisBlood-Based Biomarker ValidationNeuroimaging Biomarker PanelsCognitive Impairment EtiologyDigital Biomarker DevelopmentComputational Disease ModelingDisease Progression ForecastingScalable Biomarker ValidationTBI vs AD/ADRD DifferentiationBiological Signature DevelopmentPrognostic Marker DevelopmentCognitive Decline Prediction Models

Probable LBNL Areas

BSACSAEESAETALD· Clinical Trial Design

Focus Areas

Example Priorities:
  • Understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions
  • Development and evaluation of methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD
  • Examining differential risk pathways in vulnerable subgroups to inform precision prevention strategies
  • Link service-related exposures to specific AD/ADRD biological and clinical pathways, with emphasis on differential risk in vulnerable subgroups
  • Quantify independent and combined effects of military-relevant risk factors across Veteran and military cohorts
  • Validating blood-based or neuroimaging biomarker panels in Veteran cohorts younger than 65 to characterize the etiology of cognitive impairment and Alzheimer's disease and related dementias
Specific Technical Skills:
EpidemiologyBiostatisticsBiomarker ValidationNeuroimagingPrecision MedicineClinical Trial DesignMilitary HealthGenomicsProteomicsCohort Studies
Potential PIs for this Area:
NameScoreOrganization
Daniel Rokhsar0.75BSA | DOE Joint Genome Institute | JGI Science Dept · Genomics
Jeremy Schmutz0.75BSA | DOE Joint Genome Institute | JGI Science Dept · Genomics
Christopher Petzold0.75BSA | Biological Systems & Engineering | Biodesign Dept · Proteomics
Kevin Fan0.74LD | LD | Strategic Partnerships · Neuroimaging
Jian-Hua Mao0.72BSA | Biological Systems & Engineering | Department of BioEngineering and BioMedical Sciences · Precision Medicine
Karthik Shekhar0.72BSA | Biological Systems & Engineering | Biodesign Dept · Neuroimaging
Meghana Faltane0.72BSA | DOE Joint Genome Institute | JGI Technology Dept · Proteomics
Li-Wen (Audrey) Wang0.72BSA | Biological Systems & Engineering | Biodesign Dept · Military Health
Jennifer Rosenbluth0.72 · Clinical Trial Design
Josh North0.70EESA | CESD | Earth System Sciences · Biostatistics
Example Priorities:
  • Development and validation of objective digital biomarkers and computational models to detect subclinical decline and forecast disease progression
  • Validate scalable, accessible biomarkers for early detection, staging, and monitoring prior to significant cognitive impairment
  • Development and validation of biological and clinical signatures that distinguish AD/ADRD from chronic sequelae of traumatic brain injury
  • Development and validation of prognostic markers and staging frameworks that predict rate of cognitive decline and identify optimal windows for disease-modifying therapies
Specific Technical Skills:
Digital HealthComputational ModelingMachine LearningBiomarker DevelopmentAssay ValidationClinical NeurologyNeuropsychologyData SciencePrognosticsMedical Imaging
Potential PIs for this Area:
NameScoreOrganization
Anna Giannakou0.76CSA | SciData | Data Science Applications · Data Science
Jinyi Qi0.75BSA | Molecular Biophysics & Integrated Bioimaging | Cellular & Tissue Image · Medical Imaging
Zixi Hu0.75CSA | AMCR | Mathematics · Computational Modeling
Talita Perciano Costa Leite0.74CSA | SciData | Data & Computational Science · Machine Learning
Drew Paine0.74CSA | SciData | Data Science Applications · Digital Health
Donghun Kim0.73ETA | Building & Industrial Energy Systems | Bldg Technologies Dept · Prognostics
Seth Carbon0.73BSA | Env. Genomics & Sys. Biology | BioSystems Data Science · Assay Validation
Jian-Hua Mao0.73BSA | Biological Systems & Engineering | Department of BioEngineering and BioMedical Sciences · Biomarker Development
Fernando Perez0.72CSA | SciData | Data Science Applications · Neuropsychology
Monte Goode0.72CSA | SciData | Data Science Applications · Clinical Neurology
Example Priorities:
  • Evaluation of evidence-based interventions to reduce care partner burnout, stress, and isolation
  • Evaluation of behavioral and non-pharmacological symptom management solutions
  • Evaluation of interventions targeting modifiable risk factors
Specific Technical Skills:
Health Services ResearchImplementation ScienceBehavioral ScienceClinical PsychologyIntervention StudiesGerontologyPatient-Centered OutcomesSymptom ManagementSocial Work ResearchPublic Health
Potential PIs for this Area:
NameScoreOrganization
C. Anna Spurlock0.72ETA | Energy Analysis | Systems & Energy Tech Analysis · Behavioral Science
Stephanie Holm0.71ETA | Energy Analysis | Systems & Energy Tech Analysis · Public Health
Drew Paine0.70CSA | SciData | Data Science Applications · Implementation Science
Raymond Lee0.69BSA | DOE Joint Genome Institute | JGI Technology Dept · Gerontology
Jing Ke0.69ETA | Energy Analysis | Energy Efficiency Studies · Intervention Studies
Rafael Zamora-Resendiz0.69CSA | AMCR | Computer Science · Health Services Research
Amy Kronenberg0.69BSA | Biological Systems & Engineering | Biodesign Dept · Clinical Psychology
Hannah Cohoon0.69CSA | SciData | Data Science Applications · Social Work Research
Spencer Dutton0.68ETA | Energy Analysis | Systems & Energy Tech Analysis · Symptom Management
Eleanor Zizka0.68BSA | Biological Systems & Engineering | Department of BioEngineering and BioMedical Sciences · Patient-Centered Outcomes

Potential LBNL PIs (Overall)

Note on PI Matching: These suggestions are generated through an AI-driven semantic analysis of LBNL staff profiles.

NameScoreOrganization
Georgios Pavlopoulos0.74BSA | DOE Joint Genome Institute | JGI Science Dept · Biological Signature Development
Thomas McKone0.73ETA | Energy Analysis | Systems & Energy Tech Analysis · Military Exposure Risk Analysis
Jian-Hua Mao0.73BSA | Biological Systems & Engineering | Department of BioEngineering and BioMedical Sciences · Prognostic Marker Development
Steven Hofmeyr0.73CSA | AMCR | Computer Science · Computational Disease Modeling
Harshini Mukundan0.73LD | LD | ONHS · Biological Signature Development
Jennifer Rosenbluth0.73 · Precision Prevention Strategies
Karthik Shekhar0.72BSA | Biological Systems & Engineering | Biodesign Dept · Neuroimaging Biomarker Panels
Sharon Greenblum0.72BSA | DOE Joint Genome Institute | JGI Technology Dept · Differential Risk Pathway Analysis
Harry Caufield0.71BSA | Env. Genomics & Sys. Biology | BioSystems Data Science · Disease Progression Forecasting
Kevin Fan0.71LD | LD | Strategic Partnerships · Cognitive Impairment Etiology

Fundamental Research Exemption (FRE)

Not Mentioned